{"id":"NCT00859898","sponsor":"AstraZeneca","briefTitle":"Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes","officialTitle":"A Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin 10 mg in Combination With Metformin as Initial Therapy as Compared With Dapagliflozin 10 mg Monotherapy and Metformin Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04","primaryCompletion":"2010-05","completion":"2010-05","firstPosted":"2009-03-11","resultsPosted":"2014-03-20","lastUpdate":"2016-07-07"},"enrollment":1093,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Type 2 Diabetes Mellitus"],"interventions":[{"type":"DRUG","name":"Dapagliflozin","otherNames":["Farxiga™"]},{"type":"DRUG","name":"Metformin XR","otherNames":["Glucophage®"]},{"type":"DRUG","name":"Metformin XR","otherNames":["Glucophage®"]},{"type":"DRUG","name":"dapagliflozin matching Placebo","otherNames":[]},{"type":"DRUG","name":"metformin HCl Modified Release matching Placebo","otherNames":[]}],"arms":[{"label":"Dapagliflozin + Metformin XR","type":"EXPERIMENTAL"},{"label":"Dapagliflozin + Placebo","type":"EXPERIMENTAL"},{"label":"Metformin XR + Placebo","type":"ACTIVE_COMPARATOR"}],"summary":"The primary purpose of this study is to compare the change from baseline in hemoglobin A1C achieved with dapagliflozin 10 mg in combination with metformin XR as compared with metformin XR monotherapy and compared with Dapagliflozin monotherapy, after 24 weeks of oral administration of double-blind treatment. The safety of treatment with dapagliflozin will also be assessed in this study","primaryOutcome":{"measure":"Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants","timeFrame":"Week 24","effectByArm":[{"arm":"Dapagliflozin + Metformin XR","deltaMin":-1.98,"sd":0.0759},{"arm":"Dapagliflozin","deltaMin":-1.45,"sd":0.0734},{"arm":"Metformin XR","deltaMin":-1.44,"sd":0.0757}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":null},{"comp":"OG001 vs OG002","p":"0.9144"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":14},"locations":{"siteCount":123,"countries":["United States","India","Mexico","Puerto Rico","Russia","South Korea"]},"refs":{"pmids":["26894924"],"seeAlso":["http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":219},"commonTop":["Diarrhoea","Urinary tract infection","Vulvovaginal mycotic infection"]}}